Citi downgraded Reata Pharmaceuticals to Neutral from Buy with a price target of $172.50, up from $127, after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash. The firm expects the deal to close “uneventfully” given that Biogen has no overlapping Friedreich’s ataxia franchise.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RETA:
- Reata Pharmaceuticals downgraded to Equal Weight from Overweight at Barclays
- Biotech Alert: Searches spiking for these stocks today
- Reata Pharmaceuticals price target raised to $173 from $85 at Baird
- Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
- Reata downgraded to Market Perform from Outperform at SVB Securities